Compare QNST & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNST | VIR |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.3M | 825.0M |
| IPO Year | 2010 | 2019 |
| Metric | QNST | VIR |
|---|---|---|
| Price | $14.44 | $5.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $25.75 | $25.73 |
| AVG Volume (30 Days) | 613.9K | ★ 2.1M |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,100,345,000.00 | $16,860,000.00 |
| Revenue This Year | $11.73 | N/A |
| Revenue Next Year | $9.82 | $48.05 |
| P/E Ratio | $81.44 | ★ N/A |
| Revenue Growth | ★ 43.12 | N/A |
| 52 Week Low | $12.98 | $4.16 |
| 52 Week High | $25.50 | $14.45 |
| Indicator | QNST | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 42.12 |
| Support Level | $14.43 | $6.49 |
| Resistance Level | $15.08 | $6.75 |
| Average True Range (ATR) | 0.49 | 0.48 |
| MACD | 0.04 | -0.09 |
| Stochastic Oscillator | 39.58 | 18.63 |
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.